thalidomide has been researched along with Colitis in 21 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Colitis: Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To observe the effects of thalidomide on 2,4,6-trinitrobenzenesulfonic acid- (TNBS-) induced experimental colitis in rats and to explore the possible mechanism of thalidomide in the treatment of CD." | 7.96 | Protective Effect of Thalidomide on 2,4,6-Trinitrobenzenesulfonic Acid-Induced Experimental Colitis in Rats via the Inhibition of T Helper 17 Cells. ( Jin, S; Li, D; Luan, X; Tian, F; Xie, Y; Yan, B, 2020) |
| "Thalidomide was effective in the management of TNBS-induced colitis in young rats." | 7.80 | Efficacy of thalidomide on trinitrobenzene sulfonate-induced colitis in young rats and its mechanism. ( Huang, Y; Liang, Y; Xu, J; Zheng, C, 2014) |
| "To evaluated the therapeutic and prophylactic effect of thalidomide on 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis." | 7.74 | Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production. ( Carneiro, AJ; Carvalho, AT; Carvalho, J; Castelo-Branco, M; Dines, I; Elia, C; Madi, K; Pereira Junior, FA; Pereira, MG; Rocha, E; Schanaider, A; Silv, F; Souza, H; Tortori, C, 2007) |
| " The aim of the present study was to examine the effects of thalidomide treatment in the development of experimental colitis." | 7.73 | Thalidomide treatment reduces colon injury induced by experimental colitis. ( Cuzzocrea, S; De Sarro, A; Di Paola, R; Genovese, T; Mazzon, E; Muià, C, 2005) |
| " Thus, the aim of the present study was to examine the effects of thalidomide treatment on the permeability and structure of small intestine TJs in an animal model of experimental colitis induced by dinitrobenzene sulfonic acid (DNBS)." | 7.73 | Thalidomide treatment reduces the alteration of paracellular barrier function in mice ileum during experimental colitis. ( Cuzzocrea, S; Mazzon, E, 2006) |
| "To evaluate the effects of thalidomide in a model of experimental colitis." | 7.71 | Amelioration of experimental colitis by thalidomide. ( Aeed, H; Avni, Y; Bruck, R; Hershkoviz, R; Kenet, G; Shirin, H; Wardi, J; Zaidel, L, 2001) |
| "A 35-year-old male patient, known in our department since 1979 on account of a severe and complete Behçet's syndrome, was treated with thalidomide (CG-217) as a final pharmacological measure to avoid colectomy during a severe attack of Behçet colitis." | 7.68 | Treatment of severe colitis in Behçet's syndrome with thalidomide (CG-217). ( Larsson, H, 1990) |
| " Upon repeated dosing of Thali@PDA for one week, symptoms of IBD in mice were significantly relieved, and histomorphology of the colitis colons were normalized." | 5.91 | Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects. ( Bai, Y; Fang, X; Fu, B; Huang, H; Li, X; Ma, C; Meng, Z; Miao, W; Ren, H; Shen, S; Tao, X; Wang, Y; Xu, H; Xu, Y; Yang, J; Yang, Z; Yong, J, 2023) |
| "Thalidomide has been used as a treatment for various human immunodeficiency virus (HIV)-associated and non-HIV-associated illnesses, generally in cases in which inflammatory disease is refractory to standard therapy." | 5.35 | Thalidomide treatment for refractory HIV-associated colitis: a case series. ( Hay, PE; Jarvis, JN; Johnson, L; Wilkins, EG, 2008) |
| "Thalidomide treatment (400 mg/day), however, dramatically improved the colitis within 7 days: fever and diarrhoea disappearing." | 5.29 | Treatment of colitis in Behçet's disease with thalidomide. ( den Haan, P; Postema, PT; van Blankenstein, M; van Hagen, PM, 1996) |
| "Ten patients with therapy refractory IBD (nine Crohn's disease, one ulcerative colitis) received thalidomide 300 mg daily in a 12 week open label study." | 5.10 | Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. ( Bauditz, J; Lochs, H; Wedel, S, 2002) |
| "Eleven patients (nine males, mean age 33 years, range 20-77 years) with chronic inflammatory bowel disease (six Crohn's disease (CD), four ulcerative colitis (UC), one indeterminate colitis (IC)) who were symptomatic despite standard medical therapy were administered a daily dose of thalidomide for 12 weeks in an open-labeled protocol." | 5.10 | Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. ( Bariol, C; Byrnes, DJ; Edwards, PD; Field, A; Hing, M; Meagher, AP; Vickers, CR; Wettstein, AR, 2002) |
| "Thalidomide was effective in the management of TNBS-induced colitis in young rats." | 3.80 | Efficacy of thalidomide on trinitrobenzene sulfonate-induced colitis in young rats and its mechanism. ( Huang, Y; Liang, Y; Xu, J; Zheng, C, 2014) |
| " Established risk factors in IBD colitis inpatients with TE included: indwelling catheter (4/10), first-degree family member with TE (2/10), hereditary thrombophilia (3/10), smoking (1/10), oral contraceptive (1/5 females), and thalidomide (1/10)." | 3.79 | Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. ( Atkinson, BJ; Bousvaros, A; Harney, KM; Levine, AE; Lightdale, JR; Trenor, CC; Verhave, M; Zitomersky, NL, 2013) |
| "TNBS-induced colitis increased seizure susceptibility to a subconvulsive dose of pentylenetetrazole; the immunomodulator thalidomide was protective." | 3.75 | Intestinal inflammation and seizure susceptibility: understanding the role of tumour necrosis factor-alpha in a rat model. ( Avti, PK; Chakrabarti, A; Khanduja, KL; Medhi, B; Prakash, A, 2009) |
| " Thalidomide is effective in reducing the extent of arthritis as well as reducing the seizure scoring and increasing seizure onset in the adjuvant arthritis group." | 3.74 | Experimentally induced various inflammatory models and seizure: understanding the role of cytokine in rat. ( Arora, SK; Khanduja, KL; Medhi, B; Pandhi, P; Rao, RS; Saikia, UN; Toor, JS, 2008) |
| "To evaluated the therapeutic and prophylactic effect of thalidomide on 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis." | 3.74 | Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production. ( Carneiro, AJ; Carvalho, AT; Carvalho, J; Castelo-Branco, M; Dines, I; Elia, C; Madi, K; Pereira Junior, FA; Pereira, MG; Rocha, E; Schanaider, A; Silv, F; Souza, H; Tortori, C, 2007) |
| " The aim of the present study was to examine the effects of thalidomide treatment in the development of experimental colitis." | 3.73 | Thalidomide treatment reduces colon injury induced by experimental colitis. ( Cuzzocrea, S; De Sarro, A; Di Paola, R; Genovese, T; Mazzon, E; Muià, C, 2005) |
| " Thus, the aim of the present study was to examine the effects of thalidomide treatment on the permeability and structure of small intestine TJs in an animal model of experimental colitis induced by dinitrobenzene sulfonic acid (DNBS)." | 3.73 | Thalidomide treatment reduces the alteration of paracellular barrier function in mice ileum during experimental colitis. ( Cuzzocrea, S; Mazzon, E, 2006) |
| "To evaluate the effects of thalidomide in a model of experimental colitis." | 3.71 | Amelioration of experimental colitis by thalidomide. ( Aeed, H; Avni, Y; Bruck, R; Hershkoviz, R; Kenet, G; Shirin, H; Wardi, J; Zaidel, L, 2001) |
| "A 35-year-old male patient, known in our department since 1979 on account of a severe and complete Behçet's syndrome, was treated with thalidomide (CG-217) as a final pharmacological measure to avoid colectomy during a severe attack of Behçet colitis." | 3.68 | Treatment of severe colitis in Behçet's syndrome with thalidomide (CG-217). ( Larsson, H, 1990) |
| " Upon repeated dosing of Thali@PDA for one week, symptoms of IBD in mice were significantly relieved, and histomorphology of the colitis colons were normalized." | 1.91 | Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects. ( Bai, Y; Fang, X; Fu, B; Huang, H; Li, X; Ma, C; Meng, Z; Miao, W; Ren, H; Shen, S; Tao, X; Wang, Y; Xu, H; Xu, Y; Yang, J; Yang, Z; Yong, J, 2023) |
| "Thalidomide was used as treatment in colitis and arthritis group, whereas etoricoxib was used in CWG group." | 1.36 | Correlation of seizures and biochemical parameters of oxidative stress in experimentally induced inflammatory rat models. ( Khanduja, KL; Medhi, B; Pandhi, P; Rao, RS, 2010) |
| "Thalidomide has been used as a treatment for various human immunodeficiency virus (HIV)-associated and non-HIV-associated illnesses, generally in cases in which inflammatory disease is refractory to standard therapy." | 1.35 | Thalidomide treatment for refractory HIV-associated colitis: a case series. ( Hay, PE; Jarvis, JN; Johnson, L; Wilkins, EG, 2008) |
| "Thalidomide treatment (400 mg/day), however, dramatically improved the colitis within 7 days: fever and diarrhoea disappearing." | 1.29 | Treatment of colitis in Behçet's disease with thalidomide. ( den Haan, P; Postema, PT; van Blankenstein, M; van Hagen, PM, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 13 (61.90) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Meng, Z | 3 |
| Fu, B | 3 |
| Yang, Z | 3 |
| Xu, Y | 3 |
| Huang, H | 3 |
| Bai, Y | 3 |
| Fang, X | 3 |
| Shen, S | 3 |
| Yang, J | 3 |
| Yong, J | 3 |
| Tao, X | 3 |
| Ma, C | 3 |
| Miao, W | 3 |
| Ren, H | 3 |
| Wang, Y | 3 |
| Xu, H | 3 |
| Li, X | 3 |
| Xie, Y | 1 |
| Li, D | 1 |
| Luan, X | 1 |
| Jin, S | 1 |
| Yan, B | 1 |
| Tian, F | 1 |
| Zitomersky, NL | 1 |
| Levine, AE | 1 |
| Atkinson, BJ | 1 |
| Harney, KM | 1 |
| Verhave, M | 1 |
| Bousvaros, A | 1 |
| Lightdale, JR | 1 |
| Trenor, CC | 1 |
| Fakhoury, M | 1 |
| Coussa-Charley, M | 1 |
| Al-Salami, H | 1 |
| Kahouli, I | 1 |
| Prakash, S | 1 |
| Xu, J | 1 |
| Zheng, C | 1 |
| Huang, Y | 1 |
| Liang, Y | 1 |
| Rao, RS | 2 |
| Medhi, B | 3 |
| Saikia, UN | 1 |
| Arora, SK | 1 |
| Toor, JS | 1 |
| Khanduja, KL | 3 |
| Pandhi, P | 2 |
| Sokol, H | 1 |
| Suarez, F | 1 |
| Meatchi, T | 1 |
| Malamut, G | 1 |
| Pocidalo, MA | 1 |
| Blanche, S | 1 |
| Cellier, C | 1 |
| Hermine, O | 1 |
| Prakash, A | 1 |
| Avti, PK | 1 |
| Chakrabarti, A | 1 |
| Mazzon, E | 2 |
| Muià, C | 1 |
| Di Paola, R | 1 |
| Genovese, T | 1 |
| De Sarro, A | 1 |
| Cuzzocrea, S | 2 |
| Kirkham, SE | 1 |
| Lindley, KJ | 1 |
| Elawad, MA | 1 |
| Blanshard, C | 1 |
| Shah, N | 1 |
| Chidlow, JH | 1 |
| Langston, W | 1 |
| Greer, JJ | 1 |
| Ostanin, D | 1 |
| Abdelbaqi, M | 1 |
| Houghton, J | 1 |
| Senthilkumar, A | 1 |
| Shukla, D | 1 |
| Mazar, AP | 1 |
| Grisham, MB | 1 |
| Kevil, CG | 1 |
| Carvalho, AT | 1 |
| Souza, H | 1 |
| Carneiro, AJ | 1 |
| Castelo-Branco, M | 1 |
| Madi, K | 1 |
| Schanaider, A | 1 |
| Silv, F | 1 |
| Pereira Junior, FA | 1 |
| Pereira, MG | 1 |
| Tortori, C | 1 |
| Dines, I | 1 |
| Carvalho, J | 1 |
| Rocha, E | 1 |
| Elia, C | 1 |
| Johnson, L | 1 |
| Jarvis, JN | 1 |
| Wilkins, EG | 1 |
| Hay, PE | 1 |
| Postema, PT | 1 |
| den Haan, P | 1 |
| van Hagen, PM | 1 |
| van Blankenstein, M | 1 |
| Lienenlüke, B | 1 |
| Stojanovic, T | 1 |
| Fiebig, T | 1 |
| Fayyazi, A | 1 |
| Germann, T | 1 |
| Hecker, M | 1 |
| Kenet, G | 1 |
| Wardi, J | 1 |
| Avni, Y | 1 |
| Aeed, H | 1 |
| Shirin, H | 1 |
| Zaidel, L | 1 |
| Hershkoviz, R | 1 |
| Bruck, R | 1 |
| Bauditz, J | 1 |
| Wedel, S | 1 |
| Lochs, H | 1 |
| Bariol, C | 1 |
| Meagher, AP | 1 |
| Vickers, CR | 1 |
| Byrnes, DJ | 1 |
| Edwards, PD | 1 |
| Hing, M | 1 |
| Wettstein, AR | 1 |
| Field, A | 1 |
| Larsson, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Open Clinical Trial of Thalidomide in the Treatment of Chronic Radiation Proctitis With Intractable Bleeding[NCT04680195] | Phase 2 | 62 participants (Anticipated) | Interventional | 2020-12-14 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for thalidomide and Colitis
| Article | Year |
|---|---|
Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease.
Topics: Adult; Anti-Inflammatory Agents; Cells, Cultured; Colitis; Colitis, Ulcerative; Crohn Disease; Dose- | 2002 |
Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease.
Topics: Adult; Aged; Colitis; Colitis, Ulcerative; Colonoscopy; Crohn Disease; Female; Humans; Immunosuppres | 2002 |
19 other studies available for thalidomide and Colitis
| Article | Year |
|---|---|
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf | 2023 |
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf | 2023 |
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf | 2023 |
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf | 2023 |
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf | 2023 |
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf | 2023 |
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf | 2023 |
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf | 2023 |
Polydopamine-coated thalidomide nanocrystals promote DSS-induced murine colitis recovery through Macrophage M2 polarization together with the synergistic anti-inflammatory and anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Colitis; Cytokines; Dextran Sulfate; Inf | 2023 |
Protective Effect of Thalidomide on 2,4,6-Trinitrobenzenesulfonic Acid-Induced Experimental Colitis in Rats via the Inhibition of T Helper 17 Cells.
Topics: Animals; Colitis; Colon; Rats; Rats, Sprague-Dawley; Th17 Cells; Thalidomide; Trinitrobenzenesulfoni | 2020 |
Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease.
Topics: Adolescent; Adult; Antibodies, Anticardiolipin; Anticoagulants; Catheterization; Catheters, Indwelli | 2013 |
Use of artificial cell microcapsule containing thalidomide for treating TNBS-induced Crohn's disease in mice.
Topics: Alginates; Animals; Anti-Inflammatory Agents; Biomarkers; Capsules; Chemistry, Pharmaceutical; Colit | 2014 |
Efficacy of thalidomide on trinitrobenzene sulfonate-induced colitis in young rats and its mechanism.
Topics: Animals; Colitis; Cytokines; Inflammatory Bowel Diseases; Interleukin-10; Interleukin-1beta; NF-kapp | 2014 |
Experimentally induced various inflammatory models and seizure: understanding the role of cytokine in rat.
Topics: Acetic Acid; Analysis of Variance; Animals; Arthritis; Colitis; Cyclooxygenase Inhibitors; Cytokines | 2008 |
Thalidomide as a treatment for refractory CGD colitis.
Topics: Biopsy; Colitis; Diagnosis, Differential; Follow-Up Studies; Granulomatous Disease, Chronic; Humans; | 2009 |
Intestinal inflammation and seizure susceptibility: understanding the role of tumour necrosis factor-alpha in a rat model.
Topics: Animals; Brain; Catalase; Colitis; Colon; Disease Models, Animal; Female; Glutathione Peroxidase; Li | 2009 |
Correlation of seizures and biochemical parameters of oxidative stress in experimentally induced inflammatory rat models.
Topics: Animals; Arthritis, Experimental; Colitis; Disease Models, Animal; Granuloma; Inflammation; Lipid Pe | 2010 |
Thalidomide treatment reduces colon injury induced by experimental colitis.
Topics: Animals; Colitis; Colon; Cytokines; Disease Models, Animal; Immunohistochemistry; Immunosuppressive | 2005 |
Thalidomide treatment reduces the alteration of paracellular barrier function in mice ileum during experimental colitis.
Topics: Animals; Colitis; Dinitrobenzenes; Disease Models, Animal; Fluorescent Antibody Technique, Indirect; | 2006 |
Treatment of multiple small bowel angiodysplasias causing severe life-threatening bleeding with thalidomide.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Angiography; Blood Transfusion; Capsule Endoscopy; Child; C | 2006 |
Differential angiogenic regulation of experimental colitis.
Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; CD4-Positive T-Lymphocytes; Colitis; Colon; Disease | 2006 |
Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production.
Topics: Animals; CD4-Positive T-Lymphocytes; Colitis; Colon; Gene Expression Regulation; Immunosuppressive A | 2007 |
Thalidomide treatment for refractory HIV-associated colitis: a case series.
Topics: Adult; Colitis; Colon; Colonoscopy; HIV Infections; Humans; Immunosuppressive Agents; Intestinal Muc | 2008 |
Treatment of colitis in Behçet's disease with thalidomide.
Topics: Adult; Behcet Syndrome; Colitis; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, B | 1996 |
Thalidomide impairment of trinitrobenzene sulphonic acid-induced colitis in the rat - role of endothelial cell-leukocyte interaction.
Topics: Animals; CD40 Ligand; Cell Adhesion; Colitis; Colon; Endothelium; Gene Expression Regulation; Humans | 2001 |
Amelioration of experimental colitis by thalidomide.
Topics: Alkylating Agents; Animals; Colitis; Immunosuppressive Agents; Iodoacetamide; Rats; Thalidomide; Tum | 2001 |
Treatment of severe colitis in Behçet's syndrome with thalidomide (CG-217).
Topics: Adult; Behcet Syndrome; Colitis; Humans; Male; Thalidomide | 1990 |